BNC
Biotechnology, Next challenge CREATING A BETTER LIFE
Business Philosophy
BNC KOREA researches and develops strategic application products that will lead the next-generation bio markets for medical devices, pharmaceuticals and cosmeceutical products containing physiologically active substances by processing biomaterials such as hyaluronic acid and collagen.
As a world-class biotechnology company, BNC KOREA will continue to help people live more enjoyable life through continuous research and development using cutting-edge application technology based on biomaterials.
Company Overview
- Company Name : BNC KOREA, INC.
- CEO: Wangyu Choi
- Date of Incorporation: 8/1/2007
- Employees: 111 (As of 2020)
- Laboratory Personnel: 21persons
- Capital: 3,873 mill. USD , as of April 2020
- Main Business: Development and production
of biomaterials for medicine
-
01
Korean Bio-Venture
- · Growth : R&D-oriented
- · Profitability :Securing of independent finances
for R&D through a wide range of profitable businesses
-
02
Differentiated Bio-tech Expertise
- · Self-developed HA Filler technology
- · Self-developed HA Anti-Adhesion barrier gel
and collagen wound dressings - · Korea-granted patent for HA cross-linkage technology
- · Korea-granted patent for collagen wound dressings
containing antibiotic
-
03
Future Market Leadership
- · Preventive target marketing. Aiming
at the future marketability of certain markets,
such as the wound dressing market. - · Securing new natural-medicine aesthetic
technology - · Aiming for the future global
pharmaceutical market
- · Preventive target marketing. Aiming